#AKTX hashtag - Bluesky

7 hours ago

Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing Akari Therapeutics (Nasdaq: AKTX) announced a strategic partnership with WuXi XDC to accelerate development of its novel PH1 ADC payload and advance lead program AKTX-101. Akari aims to accelerate an IND filing by late 2026 and begin a Phase 1 trial in late 2026 or early 2027, subject to regulatory clearance.The collaboration targets RNA splicing modulation as a differentiated ADC mechanism after preclinical anti-tumor regression and complete remissions versus comparators.

#AKTX Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

2 weeks ago

Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 Akari Therapeutics (Nasdaq: AKTX) announced an abstract accepted for a poster at the American Association for Cancer Research Annual Meeting 2026, April 17–22, 2026.The poster, "Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breast," will be presented April 20, 2026, 2:00–5:00 PM PT in Poster Section 19 and posted online after 5:00 PM PT.

#AKTX Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

2 weeks ago

Akari Therapeutics Announces ADS Ratio Change Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced that the Company will change the ratio of its American

#AKTX Akari Therapeutics Announces ADS Ratio Change

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

3 weeks ago

Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology

#AKTX Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors Akari Therapeutics (NASDAQ: AKTX) filed U.S. provisional patent No. 63/958,508 for AKTX-102, a CEACAM5-targeted ADC that pairs a novel antibody construct with Akari’s PH1 spliceosome payload.The filing claims composition-of-matter protection for antibody design and ADC constructs and expands Akari’s PH1 patent family. CEACAM5 expression cited: 80–90% of gastrointestinal cancers, ~30% bladder, 25% lung adenocarcinomas, up to 50% luminal A breast. Akari plans IND-enabling work for AKTX-101 with FDA interactions in H1 2026 and aims for IND/CTA submission end-2026/early-2027.

#AKTX Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today issued the following letter to shareholders from its President and Chief Executive Officer,

#AKTX Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial Akari Therapeutics (Nasdaq: AKTX) has initiated GMP manufacturing for its lead ADC program, AKTX-101, selecting WuXi XDC as exclusive CDMO partner to perform IND-enabling work.AKTX-101 uses Akari’s proprietary PH1 payload, described as an RNA-splicing modulator combining cytotoxic and immuno-oncology mechanisms. Akari expects this GMP material to support a Phase 1 first-in-human study planned for late 2026 or early 2027, subject to regulatory clearance.

#AKTX Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Akari Therapeutics (NASDAQ: AKTX) released a Virtual Investor “What This Means” segment on Dec. 18, 2025 featuring President and CEO Abizer Gaslightwala.The video covers Akari’s spliceosome-modulating payload PH1, new preclinical data for lead ADC AKTX-101 in hard-to-treat KRAS‑mutant pancreatic cancer, and the company’s plan to advance AKTX-101 into clinical testing by late 2026/early 2027. The segment is available to watch online.

#AKTX Akari Therapeutics Releases Virtual Investor “What This Means” Segment

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

3 months ago

Trade Alerts, Monday December 16, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading, Tue Dec 16th - #VBIX #SVRE #DXST #CVKD #ZYXI #LWLG #IRBT #DFLI #CLLS #AKTX - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market Akari Therapeutics (Nasdaq: AKTX) announced a financing expected to raise approximately $5.0 million through a registered direct offering and concurrent private placement of a total of 12,607,487 ADSs (plus matching unregistered warrants).The registered direct portion comprises 10,043,774 ADSs and Series G warrants at a combined price of $0.3883 per ADS and warrant; the private placement covers 2,563,713 pre-funded warrants and warrants at a combined price of $0.4041. Existing note holders will convert ~$2.50 million of debt into pre-funded warrants and warrants. More than $1 million of new cash comes from directors, officers and management. Proceeds will fund R&D, working capital and general corporate purposes; closing expected on or about Dec 17, 2025.

#AKTX Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer Akari Therapeutics (Nasdaq: AKTX) reported preclinical data showing its Trop2-targeting ADC AKTX-101 has single-digit nanomolar cytotoxic potency in K-Ras G12V pancreatic ductal adenocarcinoma (PDAC) cell lines and outperformed daraxonrasib in multiple PDAC cell lines.The release notes Trop2 is highly expressed in K-Ras mutated PDAC, AKTX-101 carries a spliceosome-modulating payload PH1, and the company expects a first-in-human trial in late 2026 with preliminary safety and efficacy results in 2027.

#AKTX Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

#AKTX Akari Therapeutics Announces Release of the Next CEO Corner Segment

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available Akari Therapeutics (Nasdaq: AKTX) announced its SITC 40 abstract and presentations on November 7 and 9, 2025 describing preclinical immune mechanism data for its novel ADC payload PH1.The company reports that a Trastuzumab–PH1 ADC produced higher rates of complete colon-tumor regressions versus a comparator microtubule-inhibitor ADC when combined with an anti‑PD‑1 checkpoint inhibitor. The PH1 combination is attributed to neoantigen-driven immune activation, antigen-presenting cell, B-cell and T-cell engagement, and expansion of tumor‑killing gamma‑delta T cells. Poster and oral presentation details and times are provided for the SITC Annual Meeting.

#AKTX Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Akari Therapeutics Announces Launch of CEO Corner Platform Akari Therapeutics (Nasdaq: AKTX) launched a new CEO Corner platform on Oct 22, 2025 to deliver expanded perspective on press releases, corporate developments and pipeline progress.The video platform features Abizer Gaslightwala, President and CEO, and allows interested parties to ask questions and submit topics for future videos. The CEO Corner is accessible on the company website.

#AKTX Akari Therapeutics Announces Launch of CEO Corner Platform

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Akari Therapeutics Announces $2.5 Million Registered Direct Offering Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has entered into a definitive agreement for the issuance and sale of an

#AKTX Akari Therapeutics Announces $2.5 Million Registered Direct Offering

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed two new provisional patent applications with the United States Patent and

#AKTX Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting Akari Therapeutics (Nasdaq: AKTX) announced an abstract accepted for an oral presentation at the 40th Annual SITC Meeting on Nov 5-9, 2025 in National Harbor, MD. The oral talk, titled "A Novel Splicing-Targeted ADC Payload Drives Immune Activation, Synergy with Checkpoint Inhibitors, and Enhanced Therapeutic Potential beyond Cytotoxicity," will be presented by Satyajit Mitra, Ph.D. on Sunday, Nov 9, 2025 at 11:05 AM ET in the Potomac Ballroom. A related poster will be presented on Friday, Nov 7, 2025 in Prince George ABC Exhibit Halls. For more details see sitcancer.org.

#AKTX Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1 Akari Therapeutics (NASDAQ: AKTX) has announced promising preclinical data for its novel ADC spliceosome modulating payload, PH1, targeting hormone refractory prostate cancer. The data demonstrates PH1's ability to suppress AR-V7 receptor levels, which drives metastatic castration resistant prostate cancer (mCRPC) progression.The research showed PH1's effectiveness in both hormone-refractory and hormone-sensitive prostate cancer models. In hormone-sensitive cases, PH1 showed additive effects when combined with existing treatments like Xtandi and Erleada. This suggests potential for developing first-line combination therapies and addressing the significant unmet need in ARPI-resistant cases, where current treatment options are limited.

#AKTX Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Revolutionary Spliceosome Cancer Treatment: Akari Files Patent for First-in-Class ADC Platform Technology Biotech firm Akari Therapeutics files USPTO patent for novel ADC platform using PH1 payload to target cancer through spliceosome modulation. Advances AKTX-101 program for Trop2-targeting therapy.

#AKTX Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Akari Therapeutics Reveals Breakthrough Progress in Cancer-Fighting Drug Development Discover how Akari's innovative spliceosome modulator PH1 targets cancer cell growth. CEO details latest research developments in exclusive investor presentation. Get insights.

#AKTX Akari Therapeutics Releases Virtual Investor “What This Means” Segment

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Akari Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on developing novel immuno-oncology payload antibody drug conjugates (ADCs), announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.During the event, President and CEO Abizer Gaslightwala shared insights about his career journey, his commitment to the company, and his enthusiasm for Akari's development programs. The presentation is now accessible on-demand through virtualinvestorco.com and the company's investor relations website.

#AKTX Akari Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Akari Therapeutics Expands Global IP Portfolio: Key Patent Win for Cancer Drug Platform in India New India patent strengthens Akari's ADC technology portfolio for cancer treatments. Covers proprietary payload and linker technology. Learn strategic impact.

#AKTX Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Oncology Deal Veteran Mark Kubik Joins Akari Therapeutics to Accelerate ADC Pipeline Growth Watch exclusive interview with Mark Kubik, whose deal-making expertise brought multiple cancer therapies to market. Learn his vision for Akari's ADC pipeline. See video

#AKTX Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Akari Therapeutics (NASDAQ: AKTX) reported Q1 2025 financial results and provided updates on its ADC development program. The company is developing novel Antibody Drug Conjugates with immuno-oncology payloads for cancer treatment, with its lead asset AKTX-101 targeting Trop2. The company appointed Mark Kubik as Head of Business Development - Oncology.Financial highlights include a reduced net loss of $3.7 million compared to $5.6 million in Q1 2024. R&D expenses decreased to $0.8 million from $2.3 million, while G&A expenses dropped to $2.7 million from $3.7 million. The company held $2.6 million in cash as of March 31, 2025, with an additional $4.0 million received in April from a March 2025 offering that raised $6.0 million net.Key upcoming milestones include presenting preclinical data for their PH1 payload ADC in H2 2025, exploring AKTX-101 in various solid tumors, and seeking strategic partnerships.

#AKTX Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Akari Therapeutics Transforms: Next-Gen Cancer Drug Shows Promise Amid 2024 Results Novel ADC platform AKTX-101 shows superior preclinical results for solid tumors. New CEO appointed as company seeks strategic partnerships with $9.2M funding secured.

#AKTX Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules Akari Therapeutics (Nasdaq: AKTX) has announced a private placement offering expected to raise $7.6 million in gross proceeds, with strong support from existing shareholders and board members. The financing includes the issuance of 6,637,626 unregistered American Depository Shares (ADSs) priced at $0.87 per ADS, along with Series A and B Warrants.The deal structure includes the conversion of an existing $1 million convertible note by Board Chairman Dr. Huh, with expected cash proceeds of $6.6 million before fees. The warrants will have an exercise price of $0.87 per ADS, with Series A and B having terms of one and five years respectively.Funds will be allocated towards the company's spliceosome inhibitor payload ADC technology platform, seeking license partners for its TROP-2 ADC program, and monetizing non-core assets. Paulson Investment Company serves as placement agent, with closing expected around March 5, 2025.

#AKTX Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Can These 5 Growth Drivers Make Akari Therapeutics the Next Big ADC Player? Access CEO Dr. Patel's strategic vision for Akari's ADC pipeline and growth opportunities. Key insights from Virtual Investor Conference now available.

#AKTX Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

www.stocktitan.net/news/AKTX/akari-therapeu...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Major ADC Developer Akari Opens Direct Channel to Investors Through Webull Platform Biotech firm Akari Therapeutics joins Webull's Corporate Connect Service platform to strengthen investor relations and provide real-time corporate updates and development insights.

#AKTX Akari Therapeutics Joins Webull Corporate Connect Service Platform

www.stocktitan.net/news/AKTX/akari-therapeu...